Lignaron (Lenalidomide)

Lenalidomide is indicated for several hematologic malignancies and related disease pathways.

• Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients.
• Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia in patients with del(5q) cytogenetic abnormality.
• Mantle Cell Lymphoma: contributes to disease control when used in combination regimens for relapsed or refractory cases.
• Multiple Myeloma (maintenance): prolongs remission duration following autologous stem cell transplantation in eligible patients.
• Multiple Myeloma (combination): enhances anti‑myeloma activity when combined with dexamethasone or proteasome inhibitors in relapsed disease.

• Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity and promoting degradation of transcription factors Ikaros and Aiolos. This results in modulation of cytokine production, inhibition of angiogenesis, and activation of T‑ and NK‑cell mediated immune responses, together leading to apoptosis of malignant plasma cells and other hematologic tumor cells. The drug also reduces adhesion of myeloma cells to the bone marrow microenvironment, further impairing tumor growth.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue
• Nausea
• Diarrhea
• Neutropenia
• Anemia
• Rash

Serious or Rare Side Effects

• Thromboembolic events (deep vein thrombosis, pulmonary embolism)
• Severe infections (sepsis, opportunistic pathogens)
• Secondary primary malignancies
• Hepatotoxicity (elevated liver enzymes, hepatitis)
• Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis)

When prescribing lenalidomide, clinicians should observe several precautionary measures to minimize risk.

• Monitor blood counts: perform regular complete blood count testing to detect neutropenia or anemia.
• Assess renal function: adjust therapy in patients with impaired kidney function.
• Evaluate pregnancy risk: enforce strict contraception and avoid use in pregnancy due to teratogenic potential.
• Review concomitant anticoagulants: consider increased thrombotic risk when combined with anticoagulant therapy.
• Avoid use in patients with known hypersensitivity: discontinue if severe allergic reaction occurs.
• Store at room temperature: keep in original packaging, protect from moisture and light.

Lenalidomide interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure.
• Anticoagulants (warfarin): heightened risk of thrombosis or bleeding.
• Immunosuppressants (e.g., cyclosporine): may augment immunomodulatory effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce drug concentrations.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal impairment.
• Live vaccines: potential for reduced vaccine efficacy.